Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-13. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
doi:10.1371/journal.pone.0010958. PMC 2881040. PMID 20532040. Sibuet, M.; Olu, K. (1998). "Biogeography, biodiversity and fluid dependence of deep-sea cold-seep communities at active and passive margins". Deep-Sea Research Part II: Topical Studies in Oceanography. 45 (1–3): 517–567. Bibcode:1998DSRII..45..517S. doi:10.1016/S0967-0645(97)00074-X. Vinn, O.; Hryniewicz, K; Little, C.T.S.; Nakrem, H.A. (2014). "A Boreal serpulid fauna from Volgian-Ryazanian (latest Jurassic-earliest Cretaceous) shelf sediments and hydrocarbon seeps from Svalbard". Geodiversitas. 36 (4): 527–540. doi:10.5252/g2014n4a2. S2CID 129587761. Retrieved 9 January 2014. Vinn, O.; Kupriyanova, E.K.; Kiel, S. (2013). "Serpulids (Annelida, Polychaeta) at Cretaceous to modern hydrocarbon seeps: Ecological and evolutionary patterns". Palaeogeography, Palaeoclimatology, Palaeoecology. 390: 35–41. Bibcode:2013PPP...390...35V. doi:10.1016/j.palaeo.2012.08.003. Retrieved 9 January 2014.
=== Space exploration === A direct search for life in Europa's ocean would today be prohibitively expensive. Impacts on Europa give us an easier way to look for evidence of life there. Every time a major impact occurs on Europa, a vast quantity of water is splashed from the ocean into the space around Jupiter. Some of the water evaporates, and some condenses into snow. Creatures living in the water far enough from the impact have a chance of being splashed intact into space and quickly freeze-dried. Therefore, an easy way to look for evidence of life in Europa's ocean is to look for freeze-dried fish in the ring of space debris orbiting Jupiter. Freeze-dried fish orbiting Jupiter is a fanciful notion, but nature in the biological realm has a tendency to be fanciful. Nature is usually more imaginative than we are. ...To have the best chance of success, we should keep our eyes open for all possibilities.
The milli mass unit or (mmu) is used as a unit of mass by some scientific authors even though this unit is not defined by the IUPAP red book nor by the IUPAC green book. It is a short form of the more formally correct "milli unified atomic mass unit" (mu) and equivalent to 1/1000 of the unified atomic mass unit (u). A more modern name is the millidalton (mDa) since the "unified atomic mass unit" has is being superseded by the dalton (1 Da = 1 u). Since 1961 the unified atomic mass unit "u" has been defined as 1⁄12 the mass of 12C. Before that the atomic mass unit "amu" was defined as 1⁄16 the mass of 16O (physics) and as 1⁄16 the mass of O (chemistry). Thus the publication date in literature ought to be heeded when reading about the milli mass unit as its name does not reveal whether it refers to the old amu or the newer u. The mass excess is usually indicated in mu or mmu. In mass spectrometry the mass accuracy of a mass analyzer is often indicated in mu, even though a more correct unit would be mTh (millithomson) since mass spectrometers measure the mass-to-charge ratio, not the mass. The relative mass accuracy is often indicated in ppm, even though this is no longer supported by the IUPAC green book which suggests using units like μTh/Th instead of ppm.
Sources: en.wikipedia.org
Counter-Strike (also known as Half-Life: Counter-Strike or Counter-Strike 1.6) is a 2000 tactical first-person shooter game developed by Valve Corporation and published by Sierra Studios. It is the first installment in the Counter-Strike series. The game pits two teams—the Counter-Terrorists and Terrorists—against each other in objective-based game modes. The most common objectives are bomb defusal and hostage rescue, each played on designated maps. Players begin with a knife and pistol, and they can purchase more advanced weapons and equipment with money earned through eliminating enemies or accomplishing goals. Once eliminated, players do not respawn until the end of the round. Minh Le and Jess Cliffe planned a game based on counter-terrorism in 1998 with development beginning the following year when the first few beta versions were released. Their initial version of the game started as a modification for Half-Life and gained significant popularity and interest, which attracted Valve. Valve went on to acquire the game's intellectual property and announced a partnership with Le and Cliffe. After finishing development, Counter-Strike was released by Valve for Microsoft Windows in November 2000. Several remakes and ports were released on Xbox, as well as OS X and Linux. Since its release, Counter-Strike received positive reviews from critics who praised the gameplay and its emphasis on teamwork and strategy. It has been called one of the most influential first-person shooters and noted for its realistic and tactical approach to counter-terrorism.
Work has also been done for long-chain fatty acids and found that even-numbered sites, which are thought to be derived from C2 position of the acetyl group, are more enriched in 2H than odd-numbered hydrogen that come from C1 position of the acetyl group. Duan et al. reported a strong KIE during the desaturation from oleic acid to linoleic acid. In summary, the underlying physics of SNIF-NMR enables it to measure isotopomers. Another advantage of NMR measurement over mass spectrometry is that it analyzes samples non-destructively. 2H SNIF-NMR has been well industrialized in source identification and forensics, and has contributed much to biochemical pathway studies. The application of 2H SNIF-NMR to geological records is sporadic and still needs exploring.
Drugs which help to normalize the expression of EAAT2 in this region, such as N-acetylcysteine, have been proposed as an adjunct therapy for the treatment of addiction to cocaine, nicotine, alcohol, and other drugs.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.